Reference intervals of serum hyaluronic acid corresponding to the radiographic severity of knee osteoarthritis in women

Haruka Kaneko1,2†, Muneaki Ishijima1,2,3‡, Tokuhide Doi4, Ippei Futami1,2, Lizu Liu2,3, Ryo Sadatsuki1,2, Anwarjan Yusup1, Shinnosuke Hada1,2, Mitsuaki Kubota2, Takayuki Kawasaki2, Yoshitomo Saita2, Yuji Takazawa2, Hiroshi Ikeda2, Hisashi Kurosawa5 and Kazuo Kaneko1,2,3

Abstract

Background: While serum levels of hyaluronic acid (sHA) is known to be useful for a burden of disease biomarker in knee OA, it is far from practical. The reference intervals must be established for biomarkers to be useful for clinical interpretation. The aim of this study was to establish the reference intervals of sHA corresponding to the radiographic severity of knee OA for elucidating whether sHA can be useful as a burden of disease marker for individual patient with knee OA.

Methods: 372 women with Kellgren & Lawrence grade (K/L) 1 through 4 painful knee OA were enrolled in this study. The patients included 54 with K/L 1, 96 with K/L 2, 97 with K/L 3, and 118 with K/L 4. Serum samples were obtained from all subjects on the day that radiographs taken. A HA binding protein based latex agglutination assay that employed an ELISA format was used to measure sHA. Age and BMI adjusted one way ANOVA was used to set the reference intervals of sHA.

Results: The reference intervals for sHA corresponding to the patients with K/L 4 (49.6 – 66.5 ng/ml) was established without any overlap against to those with K/L 1, 2 and 3, while those with K/L 1, 2 and 3 showed considerable overlap.

Conclusions: These results indicate that sHA can be available as a burden of disease marker for the individuals with severe knee OA (K/L 4), while it is not for those with primary to moderate knee OA (K/L 1–3).

Keywords: Osteoarthritis (OA), Hyaluronic Acid (HA), Reference intervals, Biomarker, Radiography

Background

Osteoarthritis (OA) Biomarkers Network, which was funded by National Institute of Health (NIH) and developed as a partnership with Osteoarthritis Research Society International (OARSI) and the Arthritis Foundation, proposed the BIPEDS biomarker classification (Burden of disease, Investigative, Prognostic, Efficacy of intervention, Diagnosis of the Disease and Safety of interventions) which suggests the optimal study design and analytic methods for use in OA investigations [1,2]. Burden of disease markers assess the severity of disease within a particular joint among individuals with OA typically at a single point in time. Studies of burden of disease markers require comparison with one or more gold standard methods, such as radiography, of determining disease severity [3].

The serum level of hyaluronic acid (sHA) is a potential biomarker for the establishment of a proper management system in knee OA. Although sHA has been reported to be a useful burden of disease marker in OA [4-7], it is still far from being practical.

The reference intervals for a biomarker must be established before the marker can be adequate and useful for clinical interpretation. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and...
Clinical and Laboratory Standards Institute (CLSI) have defined reference intervals as the interval between two reference limits. In most cases, reference intervals are designated as the interval between and including two numbers, an upper and lower reference limit, which are estimated to enclose a specified percentage (usually 95%) of the values for a population from which the reference subjects are drawn [8].

The purpose of this study was to establish the reference intervals of sHA corresponding to the radiographic severity of knee OA in order to allow sHA to become a more practical biomarker in knee OA.

Methods
This prospective cohort study protocol was approved by the institutional review board of Juntendo University and conducted in accordance with the Declaration of Helsinki. All patients provided their written informed consent before enrollment in this trial. Three-hundred seventy-six women ranging in age from 48 to 86 years (mean 69.1) with knee pain were recruited. Patients with knee pain complained pain in the medial femorotibial compartment of the studied knee on most days of the month prior to examination and removal of body fluids. None of the patients had experienced any traumatic episodes during this period. They fulfilled the criteria of knee OA of the medial femorotibial joint as defined by the American College of Rheumatology (ACR) criteria [9]. As several other factors, such as impaired renal, hepatic function and corticosteroid usage, affect serum HA levels, patients who had these diseases were excluded. Standing, extended and antero-posterior view, and lateral and skyline view radiographs were taken at the first visit. The staging of knee OA based on radiographic examination was assessed using Kellogren and Laurence (K/L) grading. The patients included 54 with K/L grade 1, 96 with K/L grade 2, 97 with K/L grade 3, and 118 with K/L grade 4 based on the weight-bearing antero-posterior radiographs.

Serum samples were obtained from all subjects on the day that radiographs taken. As there is a diurnal variation in HA levels [10,11], fasting blood samples were collected at late morning-early afternoon for serum analyses. The serum samples were stored at -80°C until analysis. sHA was measured using an HA binding protein based latex agglutination assay (Chugai Diagnostics, Tokyo, Japan) that employed an ELISA format and the intra-assay and inter-assay variation were less than 5%.

The analyses were performed using SPSS ver.17 (SPSS Inc., Chicago, IL). The normality of the distribution of each group was tested by Kolmogorov-Smirnoc statistics. A correlation analysis was conducted by Spearman’s correlation coefficient. Parametric comparisons were necessary for the age and body mass index (BMI) adjusted one way analysis of variance (ANOVA). However, as sHA levels of the patients did not show normal distribution, they were logarithmically transformed (ln-sHA) and the age and BMI adjusted one way ANOVA was conducted. Significant differences were evaluated if ANOVA was significant. The significance of individual differences was evaluated using the Bonferroni t method. A p-value of less than 0.05 was considered to be statistically significant.

Results
The age of the patients was significantly increased depending upon the progression of the disease (K/L grades) (r=0.46, Figure 1), as reported previously [7]. The BMI of the patients with either K/L grade 1 or 2 were significantly different from those with K/L grade 3 and 4, respectively.

The ln-sHA levels of the subjects with K/L grade 4 were significantly increased in comparison to those with K/L grade 1, 2 and 3, respectively (Table 1). On the other hand, no significant difference of the ln-sHA levels were observed between the subjects with K/L grade 3 and those with K/L grade 1 and 2 (Table 1). There were no significant differences of the ln-sHA levels between the subjects with K/L grade 1 and grade 2 (Table 1).

The means and 95% confidence interval (CI) of ln-sHA were reversed into constant sHA and the age and BMI adjusted reference intervals for sHA corresponding to the patients with K/L grade 1 to 4 were calculated (Table 2). The reference intervals for sHA corresponding to the patients with K/L grade 1, 2 and 3 overlapped considerably. However, the reference interval of sHA corresponding to the patients with K/L grade 4 did not show any overlap between those with any other grades (Table 2).
No biomarkers have so far been established as accepted tools for characterizing the status of OA [12]. This is particularly due to the fact that there are no biomarkers in OA that can characterize the disease state in an individual patient [3,13]. In addition, the burden of disease markers can be used only for clinical studies because individual values obtained in groups of patients with different degrees of OA burden overlap considerably [14]. A reexamination of the approach for reporting biomarker results was proposed to overcome this problem [12], and this study was conducted to determine whether sHA levels could be employed as a burden of disease marker for individual patients by estimating the reference intervals of sHA levels corresponding to the radiographic severity of knee OA. The results revealed that the reference intervals of sHA in patients with severe knee OA (K/L grade 4) can be estimated without overlap, while those of the patients with primary to moderate OA (K/L grade 1 to 3) overlapped, considerably. These findings indicate that sHA can be available as a burden of disease marker for severe (K/L grade 4) knee OA patients and cannot for primary to moderate (K/L grade 1, 2, and 3) knee OA patients.

A measured or observed laboratory test, such as biomarker, are established when a person (usually a patient) is compared with a reference interval for the purpose of making a medical diagnosis, therapeutic management decision, or other physiological assessment. The interpretation of clinical laboratory data is, therefore, a comparative decision-making process. This decision making process requires reliable reference intervals for the biomarkers [8]. Therefore, the establishment of the reference intervals for sHA may be useful to predict the prognosis of the disease in an individual patient, because sHA has been reported to be a biomarker that can predict the prognosis of the disease [15,16], although further study is necessary.

The burden of disease biomarkers indicates the extent or severity of disease, and therefore such biomarkers can be considered to be useful tools for the staging of the disease [13]. The sHA level has been reported to be a biomarker of radiographic knee OA [7]. In general, the severity of OA increases with age, and the sHA level was increased with age in our study (Figure 1). It is impossible to exclude the possibility that an overlap of the reference intervals for the sHA levels corresponding to the patients with K/L grade 1, 2 and 3 may be due to the influence of the extent of the disease in other joints [2]. However, even though the level in patients with K/L grade 4 must be affected by the extent of the disease in other joints, no overlap was shown for the reference interval of the sHA level corresponding to the patients with K/L grade 4. The sHA level has been reported to be a biomarker not only of the burden of disease, but also as a marker of disease progression [16]. Therefore, the result of this study could be meaningful, as we were able to identify the patients with progressive OA using the sHA level, in addition to examining the radiographic severity of OA because we cannot distinguish the patients with progressive OA from those without using solely radiography [3,5]. For example, the sHA, in addition to the radiography, may be helpful to identify patients with progressive OA for inclusion into future clinical trials of DMORDs.

This current study had some limitations. The study included only Japanese female patients in the analyses. Therefore, the findings cannot be generalized to other ethnic groups and male patients. Although sHA levels were affected by total body burden of disease [17], there was no detailed phenotyping of other joints in this study, as

Table 1 Logarithmically transformed sHA (lnHA) levels of female patients with knee OA corresponding to the K/L grade

| K/L | 1      | 2      | 3      | 4      | p for trend |
|-----|--------|--------|--------|--------|------------|
| LnHA| 3.50   | 3.55   | 3.74   | 4.05   | <0.001     |
|     | (0.11, 3.28-3.72) | (0.08, 3.39-3.71) | (0.08, 3.58-3.89) | (0.08, 3.90-4.20) |             |

*p = 1.00 (−0.41 to 0.30)

Reference interval 26.5 - 41.1 29.7 - 40.8 36.0 - 48.9 49.6 - 66.5

All analyses were adjusted for age and body mass index (BMI). Covariates appearing in the model are evaluated at the following values; age = 69.1, BMI = 24.5. A p value less than 0.05 was considered to be significant. Data indicates mean (SD, 95%CI) and p (95%CI for differences). K/L: Kellegren and Laurence grade.

Discussion

No biomarkers have so far been established as accepted tools for characterizing the status of OA [12]. This is particularly due to the fact that there are no biomarkers in OA that can characterize the disease state in an individual patient [3,13]. In addition, the burden of disease markers can be used only for clinical studies because individual values obtained in groups of patients with different degrees of OA burden overlap considerably [14]. A reexamination of the approach for reporting biomarker results was proposed to overcome this problem [12], and this study was conducted to determine whether sHA levels could be employed as a burden of disease marker for individual patients by estimating the reference intervals of sHA levels corresponding to the radiographic severity of knee OA. The results revealed that the reference intervals of sHA in patients with severe knee OA (K/L grade 4) can be estimated without overlap, while those of the patients with primary to moderate OA (K/L grade 1 to 3) overlapped, considerably. These findings indicate that sHA can be available as a burden of disease marker for severe (K/L grade 4) knee OA patients and cannot for primary to moderate (K/L grade 1, 2, and 3) knee OA patients.

A measured or observed laboratory test, such as biomarker, are established when a person (usually a patient) is compared with a reference interval for the purpose of making a medical diagnosis, therapeutic management decision, or other physiological assessment. The interpretation of clinical laboratory data is, therefore, a comparative decision-making process. This decision making process requires reliable reference intervals for the biomarkers [8]. Therefore, the establishment of the reference intervals for sHA may be useful to predict the prognosis of the disease in an individual patient, because sHA has been reported to be a biomarker that can predict the prognosis of the disease [15,16], although further study is necessary.

The burden of disease biomarkers indicates the extent or severity of disease, and therefore such biomarkers can be considered to be useful tools for the staging of the disease [13]. The sHA level has been reported to be a biomarker of radiographic knee OA [7]. In general, the severity of OA increases with age, and the sHA level was increased with age in our study (Figure 1). It is impossible to exclude the possibility that an overlap of the reference intervals for the sHA levels corresponding to the patients with K/L grade 1, 2 and 3 may be due to the influence of the extent of the disease in other joints [2]. However, even though the level in patients with K/L grade 4 must be affected by the extent of the disease in other joints, no overlap was shown for the reference interval of the sHA level corresponding to the patients with K/L grade 4. The sHA level has been reported to be a biomarker not only of the burden of disease, but also as a marker of disease progression [16]. Therefore, the result of this study could be meaningful, as we were able to identify the patients with progressive OA using the sHA level, in addition to examining the radiographic severity of OA because we cannot distinguish the patients with progressive OA from those without using solely radiography [3,5]. For example, the sHA, in addition to the radiography, may be helpful to identify patients with progressive OA for inclusion into future clinical trials of DMORDs.

This current study had some limitations. The study included only Japanese female patients in the analyses. Therefore, the findings cannot be generalized to other ethnic groups and male patients. Although sHA levels were affected by total body burden of disease [17], there was no detailed phenotyping of other joints in this study, as

Table 2 sHA reference intervals of female patients with knee OA corresponding to the K/L grade

| K/L | 1      | 2      | 3      | 4      |
|-----|--------|--------|--------|--------|
| sHA (ng/ml) | Mean | 33.0   | 34.8   | 42.0   | 57.4   |
|     | (SD)   | (2.1)  | (2.1)  | (2.0)  | (2.1)  |
| Reference interval | 26.5 - 41.1 | 29.7 - 40.8 | 36.0 - 48.9 | 49.6 - 66.5 |

Data indicates mean (SD). All analyses were adjusted for age and body mass index (BMI). Covariates appearing in the model are evaluated at the following values; age = 69.1, BMI = 24.5. K/L: Kellegren Laurence grade.
mentioned above. Thus, the contribution of other joints to the systemic levels of biomarkers cannot be addressed.

Conclusions
In conclusion, this study revealed the potential of sHA as a burden of disease biomarker for the evaluation of individual patient with severe knee OA (K/L grade 4) and, simultaneously, revealed the limitation of sHA as a burden of disease biomarker for the evaluation of individual patient with primary to moderate knee OA (K/L grade 1, 2, and 3).

Abbreviations
OA: Osteoarthritis; NIH: National Institute of Health; OARSI: Osteoarthritis Research Society International; BIPEDS biomarker classification: Burden of disease, Investigative, Prognostic, Efficacy of intervention, Diagnosis of the Disease and Safety of interventions; sHA: Serum level of hyaluronic acid; IFCC: International Federation of Clinical Chemistry and Laboratory Medicine; CLSI: Clinical and Laboratory Standards Institute; ACR: American College of Rheumatology; K/L: Kellogren and Laurence; BMI: Body mass index; ANOVA: Adjusted one way analysis of variance; In-sHA: Logarithmically transformed sHA; CI: Confidence interval.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
HK and MI have made substantial contributions to conception, design, acquisition of data, analysis and interpretation of data, and drafting the manuscript. TD has made contributions to conception, design, analysis and interpretation of data. IF, SH, TK, MK, YS, YT, and HI have made contributions to acquisition, analysis and interpretation of data. LL, RS and AY have made contributions to analysis, interpretation and statistical analysis of data. HK and MI have made substantial contributions to conception, design, acquisition of data, analysis and interpretation of data, and drafting the manuscript. All the authors also have given final approval for submitting the manuscript.

Acknowledgment
We wish to thank Dr. Hajime Kajihara, Dr. Yuichiro Maruyama, Dr. Sung-Gon Kim, and Dr. Hiroaki Kanazawa for their valuable help in data collection. We give a special thanks to Dr. Kazunori Miyake for his comment in terms of the reference interval setting. This study was funded in part by a High Technology Research Center Grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to MI. and K.K.).

Author details
1 Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan. 2 Department of Orthopaedics, Faculty of Medicine, Juntendo University, Tokyo, Japan. 3 Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan. 4 Fukuoka Clinic, Tokyo, Japan. 5 Department of Orthopaedic Surgery, Juntendo University Metropolitan Koto Geriatric Medical Center, Tokyo, Japan.

Received: 27 April 2012 Accepted: 15 January 2013
Published: 18 January 2013

References
1. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, Heinegard D, Jordan JM, Kepler TB, Lane NE, et al: Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthr Cartil 2006, 14:723–727.
2. Kraus VB, Nevitt M, Sandell L: Summary of the OA biomarkers workshop 2009—biochemical biomarkers: biology, validation, and clinical studies. Osteoarthritis Cartilage 2010, 18:742–745.
3. Ishijima M, Kurosawa H, Kaneko H, Kaneko K: Biomarkers in osteoarthritis. In Arthritis: Pathophysiology, Prevention, and Therapeutics Volume 1. Edited by Bagchi D, Moriyama H, Raychaudhuri S FL: CEC Press, Taylor & Francis Group, 2011:39–54.
4. Poole AR: NIH white paper: Biomarkers, the Osteoarthritis Initiative. Book NIH white paper: Biomarkers, the Osteoarthritis Initiative. 2000. http://www.niams.nih.gov/Funding/Funded_Research/Osteoarthritis_Initiative/agenda2000.asp.
5. Ishijima M, Wataru T, Naoto K, Kaneko H, Futami I, Yoshimura-Ishida K, Tomonaga A, Yamauchi H, Yamamoto T, Nagakura I, et al: Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis. Arthritis Res Ther 2011, 13:R22.
6. Sharif M, George E, Shepstone L, Knudson W, Thonar EJ, Cushnaghan J, Dieppe P: Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum 1995, 38:763–767.
7. Elliott AL, Kraus VB, Luta G, Stabler T, Renner JB, Woodard J, Dragomir AD, Helmick CG, Hochberg MC, Jordan JM: Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 2005, 52:105–111.
8. Horowitz GL, Altman S, Boyd JC, Ceriotti F, Garg U, Horn P, Pesce A, Sine HE, Zakowski J: Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved guideline-3rd edition. In: Book Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved guideline-3rd edition. City: 2008.
9. Atman R, Asch E, Bloch D, Boile G, Boerestein D, Brandt K, Christy W, Cooke TD, Greenland R, Hochberg M, et al: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1988, 39:1039–1049.
10. Cristone LG, Elliott AL, Stabler T, Jordan JM, Pieper CF, Kraus VB: Variation of serum hyaluronan with activity in individuals with knee osteoarthritis. Osteoarthritis Cartilage 2005, 13:837–840.
11. Kong SY, Stabler TV, Cristione LG, Elliott AL, Jordan JM, Kraus VB: Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 2006, 54:2496–2504.
12. Felson DT, Lohmander LS: Whither osteoarthritis biomarkers? Osteoarthritis Cartilage 2009, 17:419–422.
13. Kraus VB: Do biochemical markers have a role in osteoarthritis diagnosis and treatment? Best Pract Res 2006, 20:69–80.
14. Roussau JC, Delmas PD: Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 2007, 3:346–356.
15. Bele JN, Berger MA, Reijnman M, Koes BW, Biemans-Zeinstma SM: Prognostic factors of progression of osteoarthritis of the knee: a systematic review of observational studies. Arthritis Rheum 2007, 57:13–26.
16. Van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP: Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPEDS criteria. Osteoarthritis Cartilage 2010, 18:505–512.
17. Kraus VB, Kepler TB, Stabler T, Renner J, Jordan J: First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis. PLoS One 2010, 5:e9739.